Correction: Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy (JAMA Oncology (2015) DOI: 10.1001/jamaoncol.2014.206);Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy

JAMA Oncology

Volumn 1, Issue 1, 2015, Pages 69-77

  Wright, Jason D ^a,b   Tergas, Ana I ^a,b,c   Cui, Rosa ^a   Burke, William M ^a   Hou, June Y ^a   Ananth, Cande V ^a,c   Chen, Ling ^a   Richards, Catherine ^c   Neugut, Alfred I ^a,b,c   Hershman, Dawn L ^a,b,c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE EFFECTS; AGE; CHI SQUARE DISTRIBUTION; DEVICES; FACTUAL DATABASE; FEMALE; HUMAN; LEIOMYOMA; MIDDLE AGED; MORCELLATION; MULTIVARIATE ANALYSIS; MYOMECTOMY; PATHOLOGY; PATIENT SELECTION; POWER SUPPLY; PRECANCEROUS CONDITIONS; PREVALENCE; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; UTERINE NEOPLASMS;

ADULT; AGE FACTORS; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; ELECTRIC POWER SUPPLIES; FEMALE; HUMANS; LEIOMYOMA; LINEAR MODELS; MIDDLE AGED; MORCELLATION; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRECANCEROUS CONDITIONS; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UTERINE MYOMECTOMY; UTERINE NEOPLASMS;

EID: 84989775087     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0803     Document Type: Erratum

References (40)

1. Metwally M, Cheong YC, Horne AW. Surgical treatment of fibroids for subfertility. Cochrane Database Syst Rev. 2012;11:CD003857.
2. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981;36(4):433-445.
3. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94(4):435-438.
4. Wallach EE, Vlahos NF. Uterinemyomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104(2):393-406.
5. Wong L, Brun JL. Myomectomy: technique and current indications. Minerva Ginecol. 2014;66(1):35-47.
6. Parker WH. Uterinemyomas: management. Fertil Steril. 2007;88(2):255-271.
7. Marret H, Fritel X, Ouldamer L, et al; CNGOF (French College of Gynecology and Obstetrics). Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):156-164.
8. Donnez J, Tatarchuk TF, Bouchard P, et al; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409-420.
9. Panagiotopoulou N, Nethra S, Karavolos S, Ahmad G, Karabis A, Burls A. Uterine-sparing minimally invasive interventions in women with uterine fibroids: a systematic review and indirect treatment comparison meta-analysis. Acta Obstet Gynecol Scand. 2014;93(9):858-867.
10. Palomba S, Zupi E, Falbo A, et al. A multicenter randomized, controlled study comparing laparoscopic versus minilaparotomic myomectomy: reproductive outcomes. Fertil Steril. 2007;88(4):933-941.
11. Seracchioli R, Rossi S, Govoni F, et al. Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: a randomized comparison with abdominal myomectomy. Hum Reprod. 2000;15(12):2663-2668.
12. Gargiulo AR, Srouji SS, Missmer SA, Correia KF, Vellinga TT, Einarsson JI. Robot-assisted laparoscopic myomectomy compared with standard laparoscopic myomectomy. Obstet Gynecol. 2012;120(2, pt 1):284-291.
13. Kho KA, Nezhat CH. Evaluating the risks of electric uterine morcellation. JAMA. 2014;311(9):905-906.
14. Patient safety must be a priority in all aspects of care. Lancet Oncol. 2014;15(2):123.
15. Oduyebo T, Rauh-Hain AJ, Meserve EE, et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol. 2014;132(2):360-365.
16. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One. 2012;7(11):e50058.
17. US Food and Drug Administration. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids. http://www.fda.gov/downloads/MedicalDevices/Safety/AlertsandNotices/UCM393589.pdf. Accessed September, 29, 2014
18. US Food and Drug Administration. Updated laparoscopic uterine power morcellation in hysterectomy andmyomectomy: FDA safety communication. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm. Accessed December 3, 2014.
19. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23):2359-2367.
20. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353(4):349-361.
21. Wright JD, Ananth CV, Lewin SN, et al. Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA. 2013;309(7):689-698.
22. Wright JD, Tergas AI, Burke WM, et al. Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. JAMA. 2014;312(12):1253-1255.
23. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303(20):2035-2042.
24. Main ML, Hibberd MG, Ryan A, Lowe TJ, Miller P, Bhat G. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. JACC Cardiovasc Imaging. 2014;7(1):40-48.
25. Steingrub JS, Lagu T, Rothberg MB, Nathanson BH, Raghunathan K, Lindenauer PK. Treatment with neuromuscular blocking agents and the risk of in-hospital mortality among mechanically ventilated patients with severe sepsis. Crit Care Med. 2014;42(1):90-96.
26. Wright JD, Neugut AI, Ananth CV, et al. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med. 2013;173(7):559-568.
27. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626-633.
28. Wallenstein MR, Ananth CV, Kim JH, et al. Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol. 2012;119(4):709-716.
29. Wright JD, Burke WM, Wilde ET, et al. Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol. 2012;30(8):783-791.
30. Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol. 2011;117(5):1051-1059.
31. Reed SD, Newton KM, Garcia RL, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol. 2010;116(2 Pt 1):365-373.
32. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56(2):403-412.
33. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):812-819.
34. Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162(4):968-974.
35. Hagemann IS, Hagemann AR, LiVolsi VA, Montone KT, Chu CS. Risk of occult malignancy in morcellated hysterectomy: a case series. Int J Gynecol Pathol. 2011;30(5):476-483.
36. Einstein MH, Barakat RR, Chi DS, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer. 2008;18(5):1065-1070.
37. Park JY, Park SK, Kim DY, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011;122(2):255-259.
38. Kim H, Kim ML, Song T, Kim MK, Yoon BS, Seong SJ. Is myomectomy in women aged 45 years and older an effective option? Eur J Obstet Gynecol Reprod Biol. 2014;177:57-60.
39. Rivard C, Salhadar A, Kenton K. New challenges in detecting, grading, and staging endometrial cancer after uterine morcellation. J Minim Invasive Gynecol. 2012;19(3):313-316.
40. Levitz J. Health insurer to stop covering uterine procedure: Highmark says risks of power morcellation outweigh benefits. http://www.wsj.com/articles/health-insurer-to-stop-covering-uterine-procedure-1406999176. Accessed January 6, 2015.